Soluble TNFα blockade enhances trastuzumab deruxtecan antitumor effect in HER2-positive breast cancer model

被引：0
|
作者：
Bruni, Sofia
Mauro, Florencia
Proietti, Cecilia
Cordo-Russo, Rosalia
Schillaci, Roxana
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-12
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
    Negar Pourjamal
    Narjes Yazdi
    Aleksi Halme
    Vadim Le Joncour
    Pirjo Laakkonen
    Pipsa Saharinen
    Heikki Joensuu
    Mark Barok
    Clinical & Experimental Metastasis, 2024, 41 : 91 - 102
  • [22] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [23] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [24] A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
    Nguyen, Xoan
    Hooper, Morgan
    Borlagdan, Jared Paul
    Palumbo, Alison
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (11) : 1410 - 1418
  • [25] Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer
    Onishi, Mai
    Shimoi, Tatsunori
    Kitadai, Rui
    Tokura, Momoko
    Yazaki, Shu
    Sumiyoshi-Okuma, Hitomi
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Syosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1423 - S1423
  • [26] The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with carcinomatosis
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez, Patricia
    Racca, Fabricio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez-Ortega, Adela
    Fernandez Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    MED, 2025, 6 (01):
  • [27] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
    Roodhart, Jeanine M. L.
    Koopman, Miriam
    LANCET ONCOLOGY, 2024, 25 (09): : 1104 - 1105
  • [28] Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
    Visani, L.
    Ratosa, I.
    Ribnikar, D.
    Becherini, C.
    Bertini, N.
    Bonaparte, I.
    Stefanovski, D.
    Dobnikar, N.
    Desideri, I.
    Mattioli, C.
    Valzano, M.
    Banini, M.
    Salvestrini, V.
    Bernini, M.
    Tommasi, C.
    Nori, J.
    Orzalesi, L.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 60 - 61
  • [29] Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
    Fernhandho, V.
    Jhoputri, C. Fricilia
    Julian, L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [30] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Pamuk, Aylin
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 74 - 76
12345